

Nonrestrictive diet does not increase infections during post-HSCT neutropenia: data from a multicenter randomized trial

Federico Stella,^{1,*} Vincenzo Marasco,^{2,*} Giorgia Virginia Levati,² Anna Guidetti,^{1,2} Annamaria De Filippo,² Martina Pennisi,² Cecilia Vismara,¹ Rosalba Miceli,³ Silva Ljevar,³ Cristina Tecchio,⁴ Nicola Mordini,⁵ Giorgia Gobbi,² Lucia Saracino,² and Paolo Corradini^{1,2}

¹Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy; ²Division of Hematology and Bone Marrow Transplant and ³Biostatistics for Clinical Research Unit, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale dei Tumori, Milan, Italy; ⁴Department of Medicine, Section of Hematology and Bone Marrow Transplant Unit, University of Verona, Verona, Italy; and ⁵Division of Hematology, Azienda Ospedaliera S. Croce e Carle, Cuneo, Italy

Key Points

- NRD is not inferior to traditional PD during neutropenia after HSCT.
- Multiple myeloma diagnosis, antibiotic prophylaxis, and absence of mucositis reduce the risk of grade ≥ 2 infections.

Infections are a major cause of morbidity and mortality during neutropenia after hematopoietic stem cell transplantation (HSCT). The use of a low-microbial protective diet (PD) in the peritransplantation period is a standard of care, although its efficacy has never been tested prospectively. We conducted a multicenter, randomized, noninferiority trial, enrolling all consecutive adult patients undergoing high-dose induction chemotherapy or HSCT with the objective to compare nonrestrictive diet (NRD) vs PD. Overall, 222 patients were enrolled, randomly assigned, and analyzed. One hundred seventy-five subjects (79%) received autologous HSCT (auto-HSCT), 41 (18%) received allogeneic HSCT (allo-HSCT), and 6 (3%) patients received high-dose induction chemotherapy. There was no significant difference in terms of incidence of grade ≥ 2 infections and death during neutropenia in the 2 arms. In multivariable analysis, only multiple myeloma diagnosis, fluoroquinolone prophylaxis, and the absence of mucositis were associated with a lower incidence of grade ≥ 2 infections. We did not report any significant variation in terms of hospitalization length, incidence of mucositis and gastrointestinal infections, body weight, and serum albumin variations in the 2 arms. In allo-HSCT recipients, the incidence of acute graft-versus-host disease grade ≥ 3 was similar. NRD was associated with higher patient-reported satisfaction. In conclusion, NRD is not inferior to a traditional PD during neutropenia after HSCT, and our results demonstrated that implementing a restrictive diet unnecessary burdens patients' quality of life. The clinical trial was registered prospectively in the clinical trial registry of the Istituto Nazionale dei Tumori of Milan as INT54/16.

Introduction

High-dose chemotherapy followed by autologous or allogeneic hematopoietic stem cell transplantation (auto- or allo-HSCT) is a potentially curative treatment for several hematological malignancies.¹ The damage to the gastrointestinal mucosa, prolonged neutropenia consequent to chemotherapy, and immunosuppression represent major risk factors for the development of severe infections.²⁻⁵ Despite the advances in supportive care, infections remain a major cause of morbidity and mortality in the setting of HSCT.⁶

Submitted 4 May 2023; accepted 25 June 2023; prepublished online on *Blood Advances* First Edition 14 July 2023; final version published online 10 October 2023. <https://doi.org/10.1182/bloodadvances.2023010348>.

*F.S. and V.M. contributed equally as joint first authors.

Deidentified patient data are available on request from the corresponding author, Paolo Corradini (paolo.corradini@unimi.it).

The full-text version of this article contains a data supplement.

© 2023 by The American Society of Hematology. Licensed under [Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International \(CC BY-NC-ND 4.0\)](https://creativecommons.org/licenses/by-nc-nd/4.0/), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.

Various measures have been adopted to minimize the incidence of infections, including the use of a low-microbial protective diet (PD). PD traditionally consists of a cooked food diet, which restricts raw foods, fresh fruits, and vegetables.⁷ The rationale behind the use of PD is to prevent the introduction of dangerous bacteria through food into a gastrointestinal tract damaged by high-dose chemotherapy,⁷ thus limiting bacteria translocation into the bloodstream.

Recent surveys demonstrated that more than 80% of bone marrow transplantation centers continue to adopt PD in the neutropenic phase after HSCT, although a standardization of diet prescriptions is lacking.^{8,9} Moreover, a low-microbial PD is extensively used even though its efficacy was never tested prospectively and evidence-based results are lacking.^{7,10} Furthermore, a retrospective study reported a significant negative correlation between oral feeding and severe graft-versus-host disease (GVHD) incidence.¹¹ It can be postulated that the use of a less palatable, restrictive diet could reduce the oral food intake of patients undergoing allo-HSCT, exposing them to a higher risk of GVHD.¹⁰

Given the potentially harmful effect of this commonly adopted procedure and the lack of prospective evidence demonstrating its efficacy in infection prevention, we designed a prospective, multicenter, noninferiority, randomized study (NEUTRODIET) that aimed to assess the impact of diet on infection incidence and transplantation outcomes in patients undergoing auto or allo transplantation and patients in whom a period of neutropenia >7 days was expected.

Methods

Study design and patients

Since July 2016, we have conducted a prospective, multicenter, randomized (1:1), parallel-group, noninferiority phase 3 trial, enrolling all consecutive hospitalized adult patients undergoing auto- (standard myeloablative conditioning)¹² or allo-HSCT (reduced intensity conditioning [RIC] and myeloablative conditioning [MAC])¹³ and adult patients in whom a period of neutropenia >7 days was expected (ie, patients receiving induction chemotherapies for acute leukemias).

The exclusion criteria were (1) the presence of an active infection before neutropenia, (2) inability to feed orally, (3) transplantation for nonmalignant diseases, (4) haploidentical HSCT, and (5) HSCT from cord blood.

The study was conducted in Italy (3 centers located in the cities of Milan, Verona, and Cuneo) and registered prospectively in the clinical trial registry of Istituto Nazionale dei Tumori di Milan (registry number INT 54/16). The trial was approved by the local ethics committee and was conducted in accordance with principles of the Declaration of Helsinki. All the patients provided written informed consent. The study protocol synopsis is available as supplemental Table 1.

Randomization and diet

Eligible patients were randomly assigned in a 1:1 ratio to receive either PD or a nonrestrictive diet (NRD) from the start of chemotherapy and during the period of severe neutropenia (absolute neutrophil count <500/ μ l). Block randomization and stratification for transplantation type (auto-HSCT vs allo-HSCT) were planned.

The PD allowed only foods cooked at >80°C and thick peel fruits washed and peeled. The foods characterizing NRD were fresh fruits and vegetables washed and manipulated according to safe food handling practices. Extended information about diet composition is provided in Table 1. Adherence to the study was defined as daily consumption of at least 1 food among those considered to characterize PD and NRD, except for clinical limitations (mucositis, nausea, etc). Data regarding feeding information were collected using a diary filled out by the patient and checked by the nursing staff.

End points and assessments

The primary end point was the investigator-assessed incidence of infection of grade ≥ 2 ($G \geq 2$) or death during the period of neutropenia.¹⁴ The secondary preplanned end points were summarized as follows: (1) incidence of infections (both incidence of gastrointestinal tract infections and incidence of fever of unknown origin from the beginning of neutropenia until discharge), (2) nutritional status (analyzed as the variation in body weight and biochemical indicators from admission to discharge and use of parenteral/enteral nutrition), (3) duration of hospital stay (days from admission to discharge), (4) estimated overall survival at 30 days from the onset of neutropenia, and (5) incidence of acute GVHD (aGVHD) according to standard criteria¹⁴ (only applicable to patients receiving allo-HCT). Infectious and adverse events were coded and graded according to the Common Terminology Criteria for Adverse Events version 4.0. The planned follow-up was 100 days after transplantation for allo recipients and 30 days after the resolution of neutropenia for the other patients.

Microbiological surveillance

All microbial cultures that were tested as positive from the onset of neutropenia were included in the analysis. Routine surveillance was conducted weekly with a rectal swab to investigate the presence of *Salmonella* species, *Shigella* species, methicillin-resistant *Staphylococcus aureus*, vancomycin-resistant *Enterococci*, *Pseudomonas* species, carbapenem-resistant *Enterobacteriaceae*, extended-spectrum β -lactamase-producing *Enterobacteriaceae*, fungi, and yeast. A nasal swab for respiratory virus was performed according to clinical symptoms. From 2020, all patients required a negative molecular severe acute respiratory syndrome coronavirus 2 test result before hospitalization. Blood cultures and specific fluid cultures were collected only when clinically indicated.

Statistical analysis

It was estimated that 40% of patients receiving PD during neutropenia would develop a clinically relevant infection or die in the first 30 days of hospitalization.¹⁵ A noninferiority trial was designed. It was planned to enroll 222 patients with a 1:1 allocation ratio in the 2 arms (111 in the control group and 111 in the experimental group). This sample size allowed to obtain a power of 80% under the following assumptions: a significance level of 10%, a proportion of 40% of developing infections in the control group, and a noninferiority margin equal to a relative risk (RR) of 1.35. Considering a dropout rate of 10%, a total of 244 patients were to be enrolled (122 in the control group and 122 in the experimental group).

Analyses were performed in the intention-to-treat population, which included all patients who underwent randomization. For group

Table 1. Diet details

	PD	NRD
Fish and meat	Only well cooked	Only well-cooked
Vegetables	Only cooked above 80°C	Fresh vegetables allowed*
Fruit	Cooked or thick peel fruit washed and peeled	Fresh fruit allowed*
Milk	Only pasteurized	Only pasteurized
Cheese	Only pasteurized	Pasteurized and seasoned cheese without mold
Yogurt	No	Only pasteurized
Eggs	Only freeze-dried	Only cooked
Bread	Allowed	Allowed
Dessert and ice cream	Only industrial preparation	Only industrial preparation
Honey	No	Only pasteurized
Cold cuts and sausages	No	Yes single portioned

*Manipulated according to safe food handling procedures.

comparison of categorical data, Fisher exact test or χ^2 test was used. Mann-Whitney test was performed for comparison of continuous variables. Multivariable logistic regression was used to study the association of different covariates with the incidence of infection. Covariates included in the model were sex, age (>55 vs ≤55 years), allo-HSCT, dietary regimen, ≥2 previous lines of therapy, antibiotic prophylaxis, multidrug resistant (MDR) bacteria colonization at admittance, use of parenteral nutrition, any grade of mucositis, and type of diagnosis. Interactions of the dietary regimen with allo-HSCT and antibiotic prophylaxis were also explored in the multivariable model. All the reported *P* values are 2-sided and were considered statistically significant when *P* < .05. Plots and statistical analysis were performed using GraphPad Prism version 9.00 (license number RRID:SCR_002798).

Results

Patients

Overall, 247 patients were enrolled. Twenty-five patients were excluded from the final analysis: 2 patients withdrew consent, 17 were improperly enrolled for protocol violation, and 6 were lost to follow-up. Between July 2016 and March 2022, a total of 222 patients were randomly assigned and analyzed at the data cutoff: 111 were assigned to the PD arm and 111 to the NRD arm (Figure 1).

The clinical and demographic characteristics were similar between the 2 arms and are reported in Table 2. The median age was 57 years (range, 22-72 years), and 96 patients were female (43%). Surveillance rectal swabs at admission were tested positive for antibiotic-resistant gram-negative bacteria in 24 patients (11%), equally distributed between the 2 arms; extended-spectrum beta-lactamases-producing *Enterobacteriaceae* were the most frequently isolated strains (12 out of 24 patients). Gut decontamination was not proposed to any patients, whereas 125 individuals (56%) received antibiotic prophylaxis (95% with fluoroquinolones), 219 (99%) received antiviral prophylaxis (acyclovir), and 212 (95%) received antifungal prophylaxis.

One hundred seventy-five subjects (79%) received auto-HSCT (88 in the PD arm and 87 in the NRD arm), among whom the

main indication was multiple myeloma (87 out of 175; 49%), followed by non-Hodgkin lymphomas (65 out of 175; 37%). In contrast, 41 subjects (18%) received allo-HSCT (20 in the PD arm and 21 in the NRD arm), and the main indication was lymphoma (20 out of 41; 49%). In this subset, the 2 arms were well balanced in terms of donor type, conditioning regimen, GVHD prophylaxis, the use of total body irradiation, and antithymocyte globulin (supplemental Table 2). Twenty-six allo-HSCT recipients (63%) received RIC.¹⁵

Infections

No difference was found between the 2 study arms in investigator-assessed cumulative incidence of *G* ≥2 infections and death during the period of neutropenia. Globally, 140 cases of *G* ≥2 infections were reported; 72 of them occurred in patients receiving PD and 68 in those receiving NRD (65% vs 61%; RR = 1.0; 95% confidence interval [CI], 0.9-1.3; *P* = .7; Figure 2A). Only 1 death was reported at 30 days, and it was secondary to multiorgan failure in the context of cytokine release syndrome after early suspension of ruxolitinib in a patient randomly assigned to the NRD arm and affected by myeloproliferative neoplasm while undergoing allo-HSCT.

Considering auto-HSCT and allo-HSCT recipients separately, we did not find any evidence of a difference in infection incidence in the 2 diet arms. In particular, in allo-HSCT recipients, *G* ≥2 infections occurred in 95% of the patients receiving PD vs 76% of patients receiving NRD (RR = 1.2; 95% CI, 0.9-1.7; *P* = .2).

Globally, the incidence of fever of unknown origin, including febrile neutropenia with unknown origin) and sepsis was comparable in the 2 arms, with 48 cases (43%) in the PD and 37 cases (33%) in the NRD arm (RR = 1.3; 95% CI, 0.9-1.8; *P* = .1) and 10 cases (9%) in the PD and 15 (13%) in the NRD arms (RR = 0.7; 95% CI, 0.3-1.4; *P* = .4), respectively (Figure 2B). The use of antibiotic prophylaxis did not prevent severe infection (*G* ≥3): 57 out of 118 (48%) patients who received antibiotic prophylaxis vs 47 (45%) among patients who did not receive it had a severe infection (RR = 1.1; 95% CI, 0.8-1.4; *P* = .7).

To further assess the impact of the dietary regimen on the risk of *G* ≥2 infection development, we carried out a multiple logistic




Figure 1. Enrollment of patients and randomization.

regression analysis (Figure 3). The only covariates significantly associated with a lower incidence of $G \geq 2$ infections were the diagnosis of multiple myeloma ($P = .001$) and the use of antibiotic prophylaxis with quinolones (odds ratio [OR], 0.35; 95% CI, 0.17-0.71; $P = .003$), whereas the presence of any grade of mucositis was strongly associated with a higher incidence of $G \geq 2$ infections (OR, 3.95; 95% CI, 1.94-8.04; $P = .0002$).

To investigate how diet interacts with allo-HSCT and antibiotic prophylaxis, 2 multivariable models with interaction terms were fitted. In the multivariable model for the interaction between diet and allo-HSCT (supplemental Table 3), a trend of higher infections $G \geq 2$ in patients undergoing allo-HSCT among those receiving PD was observed (OR, 12.04; 95% CI, 1.19-122.09) than among those receiving NRD, even though the interaction term did not reach statistical significance (interaction $P = .0710$). The multivariable model for interaction between diet and antibiotic prophylaxis (supplemental Table 4) demonstrated that the impact of antibiotic prophylaxis on infections $G \geq 2$ was similar in the 2 study arms (interaction $P = .5444$).

With regard to gastrointestinal infections, no significant differences in the incidence of gut infection and any grade mucositis were found in the 2 arms, respectively, 14% in PD vs 14% in NRD (RR = 1.1; 95% CI, 0.6-2.0; $P > .99$) and 67% in PD vs 71% in NRD (RR = 0.9; 95% CI, 0.8-1.1; $P = .6$). Notably, in allo-HSCT recipients, the incidence of $G \geq 2$ mucositis between MACand RIC was similar (53% vs 46%; RR = 1.2; 95% CI, 0.6-2.1; $P = .7$). Surprisingly, a trend for higher GI infections with confirmed microbiological isolation in PD arms was observed but did not reach statistical significance (9% in PD vs 2.7% in NRD; RR = 3.3; 95% CI, 1.02-11; $P = .09$).

allo-HSCT: GVHD

We analyzed the frequency of GVHD in patients receiving allo-HSCT. The incidence of aGVHD $G \geq 3$ was similar between the 2 arms (20% in PD vs 9.5% in NRD [$P = .4$]; RR = 2.1; 95% CI, 0.5-9.1; $P = .4$). No differences were found between the 2 arms in terms of any grade aGVHD (35% in PD vs 29% in NRD; RR = 1.2; 95% CI, 0.5-3; $P = .7$) or intestinal aGVHD (15% in PD vs 10% in NRD; RR = 1.5; 95% CI, 0.3-7.3; $P = .7$). Dietary regimen did not affect neutrophil and platelet engraftment after allo-HSCT (data not shown).

Feeding outcomes

The incidence of nausea and diarrhea was similar between the 2 arms, respectively, 17% in PD vs 15% in NRD (RR = 1.1; 95% CI, 0.6-2.0; $P = .9$) and 31% in PD vs 34% in NRD (RR = 0.9; 95% CI, 0.6-1.3; $P = .7$). Patients randomly assigned to the NRD arm lost significantly less body weight at 1 month compared with patients in the PD arm (mean, -3.7 kg in the PD arm vs -2.7 kg in the NRD arm; $P = .04$; equal to a mean percentage of weight loss from baseline of -4.6% in the PD arm vs -3.4% in the NRD arm; $P = .03$; Figure 2C). No differences were found between arms in terms of body weight variations from admittance to discharge (mean, -3.6 kg in the PD arm vs -3.2 kg in the NRD arm; $P = .3$), body mass index variations from admittance to discharge (mean, -0.9 in the PD arm vs -0.8 in the NRD arm; $P = .7$), serum albumin variation from admittance to discharge (mean, -14.5% in the PD arm vs -18% in the NRD arm; $P = .1$; Figure 2D), or hospitalization length (mean, 21 days in the PD arm vs 22 days in the NRD arm; $P = .6$; Figure 2E). From the analysis of daily diaries filled out by patients, NRD was associated with higher satisfaction, because 16% of patients receiving PD vs 35% receiving NRD

Table 2. Patients' characteristics based on the diet assigned

	Total 222, n (%)	Diet		P value*
		PD 111, n (%)	NRD 111, n (%)	
Sex (female)	96 (43)	46 (41)	50 (45)	.7
Age, median (range)	57 (22-72)	57 (26-72)	57 (22-71)	.1
Disease				.7554
Lymphomas	105 (47)	51 (46)	54 (49)	
NHL aggressive	65 (62)	31 (61)	34 (63)	
NHL indolent	17 (16)	10 (20)	7 (13)	
HL	23 (22)	10 (20)	13 (24)	
Multiple myeloma	89 (40)	48 (43)	41 (37)	
AML	9 (4)	4 (4)	5 (4)	
Other	19 (9)	8 (7)	11 (10)	
Type of procedure				.9851
Auto-HSCT	175 (79)	88 (79)	87 (78)	
Allo-HSCT	41 (18)	20 (18)	21 (19)	
High-dose CHT	6 (3)	3 (3)	3 (3)	
Previous lines (≥2)	106 (48)	52 (47)	54 (49)	.9
Disease status at enrollment				.1233
Complete response	124 (56)	66 (60)	58 (52)	
Partial response	74 (33)	38 (34)	36 (32)	
Stable disease	10 (5)	2 (2)	8 (7)	
Progressive disease	10 (5)	3 (3)	7 (7)	
Not applicable	4 (2)	2 (2)	2 (2)	
Antimicrobial prophylaxis				
Antiviral	219 (99)	108 (97)	111 (100)	.2
Antibiotic†	125 (56)	61 (55)	64 (57)	.7
Antifungal	212 (95)	106 (95)	106 (95)	> .99
MDR colonization	24 (11)	12 (11)	12 (11)	> .99
Duration of neutropenia (days), median (range)	6 (3-22)	6 (3-20)	6 (3-22)	.4

AML, acute myeloid leukemia; high-dose CHT, high-dose chemotherapy with an expected period of neutropenia >7 days; NHL, non-Hodgkin lymphoma.

*P value resulting from a Mann-Whitney test for continuous variables and χ^2 test for categorical variables.

†Among the 125 patients who received antibiotic prophylaxis, 119 (95%) received fluoroquinolones.

reported that “diet prescription did not negatively affect my alimentation” (RR = 0.5; 95% CI, 0.3-0.8; $P = .003$; Figure 2F).

In patients requiring nutritional support, the use of parenteral nutrition was preferred over enteral nutrition (3 patients received enteral nutrition vs 55 patients received parenteral nutrition). The use of parenteral nutrition, 26 (23%) in the PD arm and 29 (26%) in the NRD arm (RR = 0.9; 95% CI, 0.6-1.4; $P = .8$) as well its duration (6.9 days in the PD arm and 6.7 days in the NRD arm; $P = .8$) was similar between the study arms.

Microbiological isolations

Details regarding microbiological isolation are listed in Table 3. The most frequently isolated bacteria from blood cultures belonged to *Enterobacteriaceae* family, and the incidence of MDR bacteria was similar in the 2 arms (1% in both arms). The most frequently isolated microorganism via the stool test was *Clostridium difficile* in both arms (3% in the PD arm vs 2% in the NRD arm).

Regardless of the diet, the use of antibiotic prophylaxis with fluoroquinolones correlates with a lower incidence of bloodstream infection (9.3% in patients receiving antibiotic prophylaxis vs 23% in patients who did not receive it; RR = 0.4; 95% CI, 0.2-0.8; $P = .002$) but, as shown earlier, it did not correlate with a lower incidence of severe infection ($G \geq 3$). The use of antibiotic prophylaxis did not affect the incidence of mucositis or stool culture positiveness rate (data not shown).

Discussion

Despite the lack of a true standardization of dietary prescription during HSCT, many centers continue to adopt a low-microbial PD.⁸ To the best of our knowledge, this is the first prospective randomized trial investigating an NRD approach in the setting of auto- and allo-HSCT.

Results of our study demonstrated that the frequency of infections, deaths, nutritional outcomes, and aGVHD were not




Figure 2. Infection, feeding outcomes, and QoL. (A) Incidence of infection G \geq 2 in the 2 study arms; (B) types of infection G \geq 2; (C) body weight variations at 1 month: change in normalized weight from baseline, expressed as a percentage; (D) albumin variation from admittance to discharge: change in normalized serum albumin from baseline, expressed as a percentage; (E) duration of the hospital stay expressed in days; and (F) patient-reported QoL. QoL, quality of life.

different between patients receiving a PD vs NRD during the period of neutropenia after HSCT or high-dose chemotherapy. Specifically, the primary end point of the study was met: the incidence of G \geq 2 infections and deaths within 30 days after HSCT was not different between the 2 arms (RR = 1; 95% CI, 0.8-1.4; $P = .9$). The noninferiority of NRD in terms of infection frequency was confirmed in all subgroups considered, with particular interest in allo-HSCT recipients (76% vs 95%), although the trial was not planned to explore this objective. Moreover, considering different conditioning regimens, we did not report any detrimental effect of NRD compared with PD, in patients receiving either MAC or RIC. The G \geq 2 mucositis incidence in allo-HSCT recipients treated with a thiotepea-based RIC was 46%, similar to the 1 reported in literature.¹⁶

The multivariable analysis identified mucositis of any grade, the absence of quinolone prophylaxis, and any diagnosis other than multiple myeloma as independent factors for the development of G \geq 2 infections. The negative role of mucositis has been widely

described by several groups and is determined by the gut damage facilitating the entrance of some microorganisms into the bloodstream with consequent bacteremia.¹⁷

In the early 2000s, a prospective randomized trial reported the efficacy of quinolones as prophylaxis in patients with neutropenia in terms of the prevention of neutropenic fever and microbiologically defined infections.¹⁸ More recently, the European Conference on Infections in Leukemia suggested caution on quinolone prophylaxis because of a lack of advantage on survival and the risk of selecting MDR strains.¹⁹ Therefore, after 2018, only a minority of transplant recipients received quinolones as bacterial prophylaxis. Regardless of the dietary regimen, we reported a reduced bacteremia frequency in patients treated with quinolones but no differences in terms of G \geq 3 infections.

The protective role of multiple myeloma diagnosis in our cohort can be explained by the absence of previous cytotoxic chemotherapies in the treatment history of these patients who usually receive auto-




Figure 3. Multivariate analysis. NRD, non-restrictive diet; PD, protective diet; F, female; M, male; Nr, number.

HSCT in the first line after an induction phase with targeted therapies (ie, bortezomib, thalidomide, or lenalidomide). A previous report suggested a correlation between induction chemotherapy

and dysbiosis, which may lead to an increased risk of gastrointestinal infection or sepsis.²⁰

Table 3. Microbiological isolation

	Total	PD	NRD
Stool culture and stool test	12	9	3
<i>Clostridium difficile</i>	5	3	2
<i>Campylobacter jejuni</i>	1	1	0
<i>Pseudomonas aeruginosa</i>	2	1	1
Adenovirus	3	3	0
Rotavirus	1	1	0
Blood culture	38	16	22
<i>Enterobacteriaceae</i>	13	6	7
<i>Escherichia coli</i>	8 (2 ESBL)	3 (2 ESBL)	5
<i>Klebsiella pneumoniae</i>	3	2	1
<i>Enterobacter cloacae</i>	2	1	1
<i>Staphylococcus</i> species	11 (0 MRSA)	3	8
<i>Pseudomonas aeruginosa</i>	2	1	1
Other	12	6	6

ESBL, extended-spectrum beta-lactamases; MRSA, methicillin-resistant *Staphylococcus aureus*.

As previously reported,²¹ in our population, colonization with MDR gram-negative bacteria influenced infection incidence or overall survival neither in the PD nor in the NRD arm. A trend toward higher gastrointestinal infections with confirmed microbiological isolation in PD arms was observed, suggesting a detrimental effect of this diet on the constitution of a functional intestinal microbiota, consistent with previously reported data.^{22,23} Furthermore, the presence of a functional microbiota has been correlated with the outcomes of allogeneic transplantations and the incidence of GVHD.²⁴ It is particularly interesting to note that in our study, the risk ratio for GVHD was twofold higher in patients who received the PD than that in those who received NRD, even if this difference did not reach statistical significance.

After HSCT, weight loss and malnutrition can arise rapidly and have long-term effects.²⁵ Nutrition is an important determinant of the patient's quality of life, and the consumption of some foods, including fresh fruit, traditionally excluded from restrictive diets, is associated with an improvement in gastrointestinal symptoms, including nausea.²⁶ Our study showed that nutritional outcomes with the use of NRD were not inferior to those of PD and that patients receiving NRD reported higher satisfaction with the diet.

These results, together with data published in settings other than after transplantation,²⁷⁻³³ demonstrate that the use of a restrictive diet is an unnecessary burden for patients' quality of life. Undoubtedly, our data are more mature in the setting of auto-HSCT, in which the use of a restrictive diet should no longer be recommended. Subgroup analysis on allo-HSCT recipients is not powered to draw practice-changing conclusions; however, it is important to note that no safety concerns have emerged regarding the use of an NRD. Consequently, further trials are needed to validate the use of NRD in the context of allo-HSCT, including haploidentical HSCT.

Acknowledgments

The authors thank the patients, their families, nurses, and data managers.

References

1. Passweg JR, Baldomero H, Bader P, et al. Hematopoietic stem cell transplantation in Europe 2014: more than 40 000 transplants annually. *Bone Marrow Transplant.* 2016;51(6):786-792.
2. Blijlevens NM, Donnelly JP, de Pauw BE. Mucosal barrier injury: biology, pathology, clinical counterparts and consequences of intensive treatment for haematological malignancy: an overview. *Bone Marrow Transplant.* 2000;25(12):1269-1278.
3. Sahin U, Toprak SK, Atilla PA, Atilla E, Demirel T. An overview of infectious complications after allogeneic hematopoietic stem cell transplantation. *J Infect Chemother.* 2016;22(8):505-514.
4. Styczyński J, Tridello G, Koster L, et al. Death after hematopoietic stem cell transplantation: changes over calendar year time, infections and associated factors. *Bone Marrow Transplant.* 2020;55(1):126-136.
5. Forcina A, Rancoita PMV, Marcatti M, et al. A new clinicobiological scoring system for the prediction of infection-related mortality and survival after allogeneic hematopoietic stem cell transplantation. *Biol Blood Marrow Transplant.* 2017;23(12):2151-2158.
6. Gooley TA, Chien JW, Pergam SA, et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. *N Engl J Med.* 2010;363(22):2091-2101.
7. van Dalen EC, Mank A, Leclercq E, et al. Low bacterial diet versus control diet to prevent infection in cancer patients treated with chemotherapy causing episodes of neutropenia. *Cochrane Database Syst Rev.* 2016;4(4):1-27.
8. Peric Z, Botti S, Stringer J, et al. Variability of nutritional practices in peritransplant period after allogeneic hematopoietic stem cell transplantation: a survey by the Complications and Quality of Life Working Party of the EBMT. *Bone Marrow Transplant.* 2018;53(8):1030-1037.
9. Toenges R, Greinix H, Lawitschka A, et al. Current practice in nutrition after allogeneic hematopoietic stem cell transplantation - results from a survey among hematopoietic stem cell transplant centers. *Clin Nutr.* 2021;40(4):1571-1577.
10. Baumgartner A, Bargetzi A, Zueger N, et al. Revisiting nutritional support for allogeneic hematologic stem cell transplantation - a systematic review. *Bone Marrow Transplant.* 2017;52(4):506-513.
11. Mattsson J, Westin S, Edlund S, Remberger M. Poor oral nutrition after allogeneic stem cell transplantation correlates significantly with severe graft-versus-host disease. *Bone Marrow Transplant.* 2006;38(9):629-633.
12. Giralt S, Ballen K, Rizzo D, et al. Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. *Biol Blood Marrow Transplant.* 2009;15(3):367-369.
13. Bacigalupo A, Ballen K, Rizzo D, et al. Defining the intensity of conditioning regimens: working definitions. *Biol Blood Marrow Transplant.* 2009;15(12):1628-1633.
14. Przepiorka D, Weisdorf D, Martin P, et al. 1994 consensus conference on acute GVHD grading. *Bone Marrow Transplant.* 1995;15(6):825-828.
15. Castagna L, Dodero A, Patriarca F, et al. Multicenter phase II study on haploidentical bone marrow transplantation using a reduced-intensity conditioning regimen and posttransplantation cyclophosphamide in patients with poor-prognosis lymphomas. *Transplant Cell Ther.* 2021;27(4):328.e1-328.e6.
16. Eder S, Labopin M, Finke J, et al. Safety and efficacy of thiotepea-based conditioning for allogeneic transplantation in AML: a survey from the ALWP of the EBMT. *Bone Marrow Transplant.* 2017;52(2):238-244.
17. van der Velden WJFM, Herbers AHE, Netea MG, Blijlevens NMA. Mucosal barrier injury, fever and infection in neutropenic patients with cancer: introducing the paradigm febrile mucositis. *Br J Haematol.* 2014;167(4):441-452.
18. Bucaneve G, Micozzi A, Menichetti F, et al. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. *N Engl J Med.* 2005;353(10):977-987.

This study was supported, in part, by AIL Milano and Provincia OdV.

Authorship

Contribution: F.S., V.M., and P.C. designed the research; F.S., V.M., M.P., G.V.L., A.G., C.V., C.T., N.M., G.G., L.S., and S.L. performed the research; R.M. and S.L. provided statistical analysis; and F.S., V.M., A.D.F., and P.C. wrote the manuscript.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Correspondence: Paolo Corradini, Hematology Division, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori and University of Milano, Via Venezian 1, 20133 Milan, Italy; email: paolo.corradini@unimi.it.

19. Mikulska M, Averbuch D, Tissot F, et al. Fluoroquinolone prophylaxis in haematological cancer patients with neutropenia: ECIL critical appraisal of previous guidelines. *J Infect.* 2018;76(1):20-37.
20. Rashidi A, Weisdorf DJ. Microbiota-based approaches to mitigate infectious complications of intensive chemotherapy in patients with acute leukemia. *Transl Res.* 2020;220(6):167-181.
21. Forcina A, Lorentino F, Marasco V, et al. Clinical impact of pretransplant multidrug-resistant gram-negative colonization in autologous and allogeneic hematopoietic stem cell transplantation. *Biol Blood Marrow Transplant.* 2018;24(7):1476-1482.
22. Trifilio SM, Pi J, Mehta J. Changing epidemiology of clostridium difficile-associated disease during stem cell transplantation. *Biol Blood Marrow Transplant.* 2013;19(3):405-409.
23. Ubeda C, Djukovic A, Isaac S. Roles of the intestinal microbiota in pathogen protection. *Clin Transl Immunology.* 2017;6(2):e128-138.
24. Staffas A, Burgos da Silva M, van den Brink MRM. The intestinal microbiota in allogeneic hematopoietic cell transplant and graft-versus-host disease. *Blood.* 2017;129(8):927-933.
25. Urbain P, Birlinger J, Lambert C, Finke J, Bertz H, Biesalski HK. Longitudinal follow-up of nutritional status and its influencing factors in adults undergoing allogeneic hematopoietic cell transplantation. *Bone Marrow Transplant.* 2013;48(3):446-451.
26. Hinkelmann JV, Possa LdO, de Oliveira CA, Faria BS, Hermsdorff HHM, Rosa CdOB. Food preferences and aversions of patients undergoing chemotherapy, radiotherapy and/or hematopoietic stem cell transplantation. *Clin Nutr ESPEN.* 2021;44(6):331-336.
27. Gardner A, Mattiuzzi G, Faderl S, et al. Randomized comparison of cooked and noncooked diets in patients undergoing remission induction therapy for acute myeloid leukemia. *J Clin Oncol.* 2008;26(35):5684-5688.
28. Moody KM, Baker RA, Santizo RO, et al. A randomized trial of the effectiveness of the neutropenic diet versus food safety guidelines on infection rate in pediatric oncology patients. *Pediatr Blood Cancer.* 2018;65(1):e26711-26719.
29. van Tiel F, Harbers MM, Terporten PHW, et al. Normal hospital and low-bacterial diet in patients with cytopenia after intensive chemotherapy for hematological malignancy: a study of safety. *Ann Oncol.* 2007;18(6):1080-1084.
30. Ball S, Brown TJ, Das A, Khera R, Khanna S, Gupta A. Effect of neutropenic diet on infection rates in cancer patients with neutropenia: a meta-analysis of randomized controlled trials. *Am J Clin Oncol.* 2019;42(3):270-274.
31. Radhakrishnan V, Lagudu PBB, Gangopadhyay D, et al. Neutropenic versus regular diet for acute leukaemia induction chemotherapy: randomised controlled trial. *BMJ Support Palliat Care.* 2022;12(4):421-430.
32. Taggart C, Neumann N, Alonso PB, et al. Comparing a neutropenic diet to a food safety-based diet in pediatric patients undergoing hematopoietic stem cell transplantation. *Biol Blood Marrow Transplant.* 2019;25(7):1382-1386.
33. Ramamoorthy V, Rubens M, Appunni S, et al. Lack of efficacy of the neutropenic diet in decreasing infections among cancer patients: a systematic review. *Nutr Cancer.* 2020;72(7):1125-1134.